Flint, SarahLevy, Cameron2022-08-102026-09-292022-08-102026-09-292022-04-152022-08-10http://arks.princeton.edu/ark:/88435/dsp0100000322nhttps://theses-dissertations.princeton.edu/handle/88435/dsp0100000322nGene replacement therapy is a rapidly growing therapeutic modality that is uniquely suited to address monogenic diseases. Many monogenic diseases afflicting the nervous and sensory nervous systems present with a progressive pathology due to death of long-lived cell types that do not replenish quickly. Due to rapid disease progression, early intervention can prevent irreversible damage and improve patient outcomes. The present study investigates AAV gene therapy clinical trial results from six monogenic diseases (Spinal Muscular Atrophy, Leber Congenital Aumorosis, Aromatic l-amino Acid Decarboxylase Deficiency, Leber Hereditary Optic Neuropathy, Choroideremia, and Retinitis Pigmentosa) to determine whether age of intervention has a significant effect on patient outcomes. The study demonstrated correlation between younger age and improved efficacy of gene therapy in three disease that met the inclusion criteria. These results support expansion of universal newborn screening protocols to include some, if not all, of the diseases investigated. Additionally, these data highlight the potential benefit of conducting clinical trials in younger patients for progressive monogenic diseases with gene therapies coming through the clinical pipeline.application/pdfenIMPACT OF AGE ON EFFICACY OUTCOME MEASURES IN PROGRESSIVE MONOGENIC DISEASES TREATED WITH AAV GENE THERAPYPrinceton University Senior Theses